Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (32)
Hala Wannous. (2023) Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome. Pediatric Nephrology 38:8, pages 2643-2648.
Crossref
Crossref
Johannes Birtel, Roselie M. Diederen, Philipp Herrmann, Sophie Kaspar, Bodo B. Beck, Sander F. Garrelfs, Bernd Hoppe & Peter Charbel Issa. (2022) The retinal phenotype in primary hyperoxaluria type 2 and 3. Pediatric Nephrology 38:5, pages 1485-1490.
Crossref
Crossref
Xuan Gang, Fei Liu & Jianhua Mao. (2023) Lumasiran for primary hyperoxaluria type 1: What we have learned?. Frontiers in Pediatrics 10.
Crossref
Crossref
Dieter Haffner & Lesley Rees. 2023. Pediatric Kidney Disease. Pediatric Kidney Disease
1517
1551
.
Bodo B. Beck, Cristina Martin-Higueras & Bernd Hoppe. 2023. Pediatric Kidney Disease. Pediatric Kidney Disease
795
819
.
Yongchang Lai, Hanxiong Zheng, Xuan Sun, Jiong Lin, Qingyi Li, Huining Huang, Yi Hou, Hongzhen Zhong, Dongfang Zhang, Tang Fucai & Zhaohui He. (2022) The advances of calcium oxalate calculi associated drugs and targets. European Journal of Pharmacology 935, pages 175324.
Crossref
Crossref
John Odhiambo, Hanika Patel, Anderson Mutuiri, Fazal Yakub & Ahmed Sokwala. (2022) A Case of Oxalate Nephropathy in a Known Diabetic Patient following Acute Alcoholic Pancreatitis. Case Reports in Nephrology 2022, pages 1-3.
Crossref
Crossref
Maria Dolores Moya-Garzon, Barbara Rodriguez-Rodriguez, Cristina Martin-Higueras, Francisco Franco-Montalban, Miguel X. Fernandes, Jose A. Gomez-Vidal, Angel L. Pey, Eduardo Salido & Monica Diaz-Gavilan. (2022) New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production. European Journal of Medicinal Chemistry 237, pages 114396.
Crossref
Crossref
Bernd Hoppe & Cristina Martin-Higueras. (2022) Improving Treatment Options for Primary Hyperoxaluria. Drugs 82:10, pages 1077-1094.
Crossref
Crossref
Yulin Fan & Zhijun Yang. (2022) Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application. Pharmaceutics 14:6, pages 1193.
Crossref
Crossref
Algera Goga & Markus Stoffel. (2022) Therapeutic RNA-silencing oligonucleotides in metabolic diseases. Nature Reviews Drug Discovery 21:6, pages 417-439.
Crossref
Crossref
Prince Singh, Peter C. Harris, David J. Sas & John C. Lieske. (2021) The genetics of kidney stone disease and nephrocalcinosis. Nature Reviews Nephrology 18:4, pages 224-240.
Crossref
Crossref
Johannes Birtel, Peter Charbel Issa, Philipp Herrmann, Bernd Hoppe & Anja Katrin Büscher. (2022) Examination of the eye and retinal alterations in primary hyperoxaluria type 1. Nephrology Dialysis Transplantation 37:2, pages 255-257.
Crossref
Crossref
Ruth Belostotsky & Yaacov Frishberg. (2022) Catabolism of Hydroxyproline in Vertebrates: Physiology, Evolution, Genetic Diseases and New siRNA Approach for Treatment. International Journal of Molecular Sciences 23:2, pages 1005.
Crossref
Crossref
Marcus J. Moeller, Rafael Kramann, Twan Lammers, Bernd Hoppe, Eicke Latz, Isis Ludwig-Portugall, Peter Boor, Jürgen Floege, Christian Kurts, Ralf Weiskirchen & Tammo Ostendorf. (2022) New Aspects of Kidney Fibrosis–From Mechanisms of Injury to Modulation of Disease. Frontiers in Medicine 8.
Crossref
Crossref
Friedrich Thaiss & Herbert J. Kramer. 2022. Therapie-Handbuch - Nephrologie. Therapie-Handbuch - Nephrologie
42
46
.
Eleanor Hay, Thomas Cullup & Angela Barnicoat. (2021) A practical approach to the genomics of kidney disorders. Pediatric Nephrology 37:1, pages 21-35.
Crossref
Crossref
Michelle A. Baum. 2022. Diagnosis and Management of Pediatric Nephrolithiasis. Diagnosis and Management of Pediatric Nephrolithiasis
159
169
.
Bernd Hoppe, Bodo B. Beck & Cristina Martin-Higueras. 2022. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases
1319
1332
.
Elisa KottosBrigitte AdamsDominique BiarentXavier Beretta-PiccoliKhalid IsmailiDavid De Bels, Patrick M. Honore & Sebastien Redant. (2021) Hyperoxaluria: An early diagnosis will allow a timely combined renal and liver transplantations to avoid irreversible damages to all other organs. Journal of Translational Internal Medicine 9:4, pages 318-322.
Crossref
Crossref
Anja Pfau, Theresa Ermer, Steven G. Coca, Maria Clarissa Tio, Bernd Genser, Martin Reichel, Fredric O. Finkelstein, Winfried März, Christoph Wanner, Sushrut S. Waikar, Kai-Uwe Eckardt, Peter S. Aronson, Christiane Drechsler & Felix Knauf. (2021) High Oxalate Concentrations Correlate with Increased Risk for Sudden Cardiac Death in Dialysis Patients. Journal of the American Society of Nephrology 32:9, pages 2375-2385.
Crossref
Crossref
Ruth Belostotsky & Yaacov Frishberg. (2020) Novel therapeutic approaches for the primary hyperoxalurias. Pediatric Nephrology 36:9, pages 2593-2606.
Crossref
Crossref
Francesco Tandoi, Davide Cussa, Licia Peruzzi, Silvia Catalano, Roberta Camilla, Giorgia Mandrile, Pier Luigi Calvo, Michele Pinon, Dominic Dell’Olio, Mauro Salizzoni, Antonio Amoroso & Renato Romagnoli. (2021) Combined liver kidney transplantation for primary hyperoxaluria type 1: Will there still be a future? Current transplantation strategies and monocentric experience. Pediatric Transplantation 25:4.
Crossref
Crossref
Arnaud Devresse, Nathalie Godefroid, Blaise Anthonissen, Laura Labriola, Catherine de Magnée, Raymond Reding, Etienne Sokal, Xavier Stephenne, Valentine Gillion & Nada Kanaan. (2021) Liver Transplantation in Primary Hyperoxaluria Type 1: We Have to Find an Alternative!. Transplantation 105:4, pages e46-e47.
Crossref
Crossref
Arnaud Devresse, Raymond Reding & Nada Kanaan. (2021) Management of primary hyperoxaluria type 1: Does liver transplantation still have a future?. Journal of Liver Transplantation 2, pages 100017.
Crossref
Crossref
Alexandre Nuzzo, Sebastien Czernichow, Alexandre Hertig, Séverine Ledoux, Tigran Poghosyan, Didier Quilliot, Maude Le Gall, André Bado & Francisca Joly. (2021) Prevention and treatment of nutritional complications after bariatric surgery. The Lancet Gastroenterology & Hepatology 6:3, pages 238-251.
Crossref
Crossref
Cristina Martin-Higueras, Markus Feldkötter & Bernd Hoppe. (2021) Is stiripentol truly effective for treating primary hyperoxaluria?. Clinical Kidney Journal 14:1, pages 442-444.
Crossref
Crossref
Arnaud Devresse, Pierre Cochat, Nathalie Godefroid & Nada Kanaan. (2020) Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives. Kidney International Reports 5:12, pages 2136-2145.
Crossref
Crossref
Caroline Kempf, Anja Pfau, Johannes Holle, Karen Müller-Schlüter, Philip Bufler, Felix Knauf & Dominik Müller. (2020) Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient. Pediatric Nephrology 35:9, pages 1787-1789.
Crossref
Crossref
Alexandre J. Debacker, Jon Voutila, Matthew Catley, David Blakey & Nagy Habib. (2020) Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug. Molecular Therapy 28:8, pages 1759-1771.
Crossref
Crossref
Lars Pape, Thurid Ahlenstiel-Grunow, Johannes Birtel, Tim U. Krohne & Bernd Hoppe. (2020) Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis. Pediatric Nephrology 35:6, pages 1121-1124.
Crossref
Crossref
Zhiqiang Chen, Peng Yuan, Xifeng Sun, Kun Tang, Haoran Liu, Shanfu Han, Tao Ye, Xiao Liu, Xiaoqi Yang, Jin Zeng, Libin Yan, Jinchun Xing, Kefeng Xiao, Zhangqun Ye & Hua Xu. (2019) Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axis. American Journal of Physiology-Renal Physiology 317:1, pages F137-F151.
Crossref
Crossref